5 Analysts Have This to Say About Esperion Therapeutics
Portfolio Pulse from Benzinga Insights
Esperion Therapeutics (NASDAQ:ESPR) has received five bullish analyst ratings in the last quarter, with an average 12-month price target of $13.4, a significant increase from the previous average of $7.75. No bearish or neutral ratings were observed.
August 04, 2023 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics has received five bullish analyst ratings in the last quarter, with an average 12-month price target of $13.4, up 72.9% from the previous average of $7.75.
The bullish ratings and increased price target indicate a positive outlook for Esperion Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100